Acumen reports FY2021 net loss $100.6M; Phase 1 ACU193 topline results expected H1 2023

Acumen Pharmaceuticals, Inc.

Cash, cash equivalents and marketable securities $225.9M at Dec 31, 2021; provides runway through 2025.
Net loss $100.6M for FY2021 includes $81.2M non-cash fair value adjustment; operating loss $19.6M.
R&D expenses $12.3M (up from $8.0M) driven by clinical trial initiation; G&A $7.3M (up from $1.4M).
Topline results from INTERCEPT-AD Phase 1 trial of ACU193 now expected first half of 2023 due to slower enrollment from COVID-19.
Kim Drapkin appointed to Board of Directors effective Apr 1, 2022; three new team members added in Q4 2021.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.